Breakthrough Nanodisc Technology Enhances HIV and Ebola Vaccine Design

Scientists have developed a new nanodisc platform that preserves HIV and Ebola viral proteins in their natural membrane environment, exposing hidden weak spots that were previously missed in traditional lab preparations. This breakthrough enables more accurate study of how broadly neutralizing antibodies interact with viral surfaces, offering a promising path toward improved vaccine design for both viruses.

The technology works by embedding transmembrane glycoproteins from HIV and Ebola into lipid bilayers that mimic the viruses’ outer membranes. This approach maintains the proteins’ correct folding and trimer structure, which is essential for studying immune targeting. In detergent-based systems commonly used in research, critical membrane-proximal epitopes are often lost, leading to inaccurate antibody binding analysis. By preserving these regions, nanodiscs allow researchers to observe how antibodies truly recognize and stop viruses in a setting that closely resembles real infection.